AIHealthcare

Natera, Inc. is a publicly traded molecular diagnostics and precision-medicine company headquartered in Austin, Texas. It develops and commercializes cell-free DNA (cfDNA), genomic, bioinformatics, and artificial-intelligence technologies for oncology, women’s health, and organ health. Its principal products include Signatera for personalized circulating-tumor-DNA and minimal-residual-disease monitoring, Panorama and Horizon for prenatal and carrier screening, and Prospera for transplant assessment. Natera launched a proprietary AI foundation-model platform in August 2025, describing applications spanning diagnostic and therapeutic innovation, biomarker discovery, clinical decision support, and drug-development collaborations. The company is a major participant in noninvasive prenatal testing and an emerging leader in molecular residual-disease testing, but it remained unprofitable in fiscal 2025 despite strong revenue growth.